TriangleHEALTH PROFESSIONAL · SOURCE READING
TKI therapy for KIT/PDGFRA wild-type GISTs
Source: Gastrointestinal Stromal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: December 13, 2024 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Context: Treatment of Metastatic or Recurrent GISTs / Treatment Options for Metastatic or Recurrent GISTs
Patients without KIT or PDGFRA variants, such as SDH-deficient and NF1-related GISTs, do not benefit from initial TKI treatment with imatinib. However, these patients may have modest response to sunitinib and regorafenib.[47] These tumors tend to have a relatively indolent course, and optimal management of these patients remains unknown. Thus, patients should be encouraged to enroll in a clinical trial, if available.
Source links and citations
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice